Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.06
(
1.20%
)
US TECH 100
25,958.80
(
1.33%
)
Dow Jones
49,447.43
(
1.88%
)
Brent Oil
92.66
(
4.26%
)
Bitcoin
73,868.06
(
-2.47%
)
News Focus
News Focus
Post# of 257426
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122876
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: willyw post# 200812

Saturday, 04/16/2016 11:25:17 AM

Saturday, April 16, 2016 11:25:17 AM

Post# of 257426
ABBV/ENTA’s ABT-493/ABT-530 data released today (#msg-121966912)* are as good as any investor could possibly have hoped for, particularly in GT3—the hardest genotype to treat for most DAA regimens.

Once upon a time, there was some doubt on this message board as to whether the ABT-493/ABT-530 combination was truly pan-genotypic. Not anymore.

*Not to be confused yesterday’s data release on the MAGELLAN-1 study in patients who failed prior all-DAA treatments (#msg-121939941, #msg-121963747).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today